West LA Times

GT Biopharma, Inc. issued the following announcement on Sept. 13. 

GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, today, announces the advancement of GTB-3650 into IND-enabling studies, with which it plans to supplant the ongoing Phase 1 program with GTB-3550.

Therapeutic and commercial advantages of GTB-3650 compared to GTB-3550 include:

• Based on second generation camelid single-domain antibody technology that holds several advantages over traditional IgG monoclonal antibodies
• Improved potency and enhanced binding affinity
• Similar preclinical safety profile
• Commercial manufacturing capabilities through arrangement with Cytovance
• Proprietary patented molecule, which unlike GTB-3550, is wholly owned by GT Biopharma

"We look forward to advancing GTB-3650 toward the clinic" noted Greg Berk, M.D., GT Biopharma's President of R&D and Chief Medical Officer. "This transition marks the next logical evolution of our TriKE® platform. As the company focuses its resources on the most promising pipeline candidates, GTB-3650 will now be able to take advantage of the strong evidence gathered from our first-generation pilot TriKE® program. Complementing this development advance, has been the transition of all manufacturing processes to Cytovance Biologics, a leading specialty cGMP contract manufacturing organization. We have now achieved another strategic milestone consistent with our mission to advance novel immuno-oncology drugs to patients with advanced cancers", commented Dr. Berk.   

Original source can be found here.

Source: GT Biopharma, Inc.